Pentoxifylline for Treatment of Resistant Major Depression

Summary

A growing body of evidence has highlighted the role of inflammation and phosphodiesterases (PDE)-related pathways in the pathogenesis of neuropsychiatric illnesses such as depression/mood disorders. Herein, we aimed to evaluate the therapeutic benefits of pentoxifylline (PTX) in the treatment of therapy-resistant depression (TRD) in adult patients with bipolar depression.

Timeline

Start

2021-12-15

Primary completion

2022-05-04

Completion

2022-06-04

Drugs

Indications